

FDA approved for adults and adolescents*
with eczema (atopic dermatitis)¹

Itch relief like that

Fast itch relief
**AS SOON AS
48 HOURS**^{2†}

Skin healing
that lasts^{2‡}

Better *days
and nights*^{1§}

Not an actual patient.

*Age 12 or older.¹

[†]PP-NRS response defined as a ≥ 4 -point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in ARCADIA 2. Significant improvement was achieved at 48 hours (9% with NEMLUVIO + TCS/TCI vs 3% with placebo + TCS/TCI, $P \leq 0.01$).²

[‡]44% of those using NEMLUVIO + TCS/TCI achieved significantly clearer skin at Week 16 vs 29% with placebo + TCS/TCI. Clear or almost clear skin was defined as 1 or below on the IGA scale, where 0 was clear and 4 was severe, with a 2-point improvement from baseline.¹

[§]As demonstrated in clinical studies by improvements in quality of life measurements including the SD-NRS for 38% of those using NEMLUVIO + TCS/TCI vs 20% with placebo + TCS/TCI.¹

IGA=Investigator's Global Assessment; PP-NRS=Peak Pruritus Numerical Rating Scale; SD-NRS=Sleep Disturbance Numerical Rating Scale; TCI=topical calcineurin inhibitors; TCS=topical corticosteroids.

Important Safety Information

Indication: NEMLUVIO[®] (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age.

Please see full [Prescribing Information](#), including Patient Information.

Is the itch of eczema a constant struggle?

Eczema can be demanding. Managing symptoms and caring for your skin takes up energy and mind space. For many, itch even impacts focus at school or work, social activities, relationships, self-esteem, and sleep.^{3,4}

Eczema can cause:

Intense and/or persistent itch³

Dry, scaly skin³

Uncomfortable or painful rashes³

Unresolved symptoms despite treatment¹

Inability to sleep or focus due to intense itch⁴

Not an actual patient.



Action you can take today

Managing eczema shouldn't have to feel like an ongoing conversation. Use the discussion guide to help your dermatologist better understand the impact of itch on your everyday life and which options are right for you.



DOWNLOAD
THE GUIDE
by scanning this code



Ask a dermatologist about **NEMLUVIO®**
for relief you can see and feel

Please see full [Prescribing Information](#), including Patient Information.

Get the relief you've been waiting for with NEMLUVIO



Itch relief that lasts
so skin can heal²



Fast itch relief—
as soon as 48 hours^{2*}



Long-lasting
skin clearance²



Fewer sleepless
nights^{1†}



Favorable
safety profile¹



~Once-monthly dosing
from the start¹

Not an actual patient.



*Data from post hoc descriptive analysis of daily PP-NRS improvement.²

†Adults and adolescents with eczema reported sleeping better while on treatment with NEMLUVIO.¹
PP-NRS=Peak Pruritus Numerical Rating Scale.

Important Safety Information


Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO. **Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:**

- are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
- are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.


What causes itch in eczema?

Eczema starts with signals beneath the skin



How NEMLUVIO stops the itch

NEMLUVIO is designed to directly block IL-31 signaling



IL-31=interleukin-31.

Please see full [Prescribing Information](#), including Patient Information.

 **nemludio**[™]
(nemolizumab-ilto) for injection
30 mg

Skin healing that lasts



26-year-old male.

67-year-old female.

Actual patients from clinical trial.
Individual results may vary.

By Week 16, 44% of those using NEMLUVIO + topicals saw an improvement of at least 75% or more in the severity of their eczema and the extent of their skin affected by it (vs 29% with placebo + topicals).^{1*}

36% had clear or almost clear skin by Week 16^{1†}

The most common side effects for those using NEMLUVIO + topicals were headache, joint pain, muscle ache, and hives. Headache was the most common at 5% (vs 4% with placebo + topicals), with each of the other side effects occurring at 1% (vs 0% with placebo + topicals).¹

NEMLUVIO was evaluated in 2 Phase 3 clinical trials and a long-term study, measuring itch, skin healing, and effect on sleep, among other factors. The studies included over 1700 adults and adolescents (aged 12 or older) with moderate-to-severe eczema (atopic dermatitis) not well-controlled by topicals.¹

Results shown are from the first clinical trial (ARCADIA 1) and the long-term study. Topicals used in the ARCADIA studies included topical corticosteroids and topical calcineurin inhibitors.¹

*Response defined as EASI-75 (improvement of at least 75%).¹

[†]Clear or almost clear skin was defined as a 1 or below on the IGA scale, where 0 was clear and 4 was severe, with a 2-point improvement from baseline.¹

[‡]Data from post hoc descriptive analysis of daily PP-NRS improvement.²

[§]Itch relief over 56 weeks was reported using the Pruritus VAS component of SCORAD, a measurement of eczema severity, where 0 was no itch and 10 was the worst itch imaginable based on an average assessment of the past 3 days or nights.²

EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; PP-NRS=Peak Pruritus Numerical Rating Scale; TCI=topical calcineurin inhibitors; TCS=topical corticosteroids; SCORAD=Scoring Atopic Dermatitis; VAS=Visual Analog Scale.



Please see full [Prescribing Information](#), including Patient Information.

Fast and lasting itch relief

NEMLUVIO quickly
relieves the urge to scratch

as soon as
48 hours^{2‡}

After 1 year of treatment

8 OUT OF 10

adults and adolescents
experienced continued itch relief^{2§}



**Better days
and nights ahead**

NEMLUVIO helped most adults and adolescents improve sleep and quality of life, as measured across factors such as the effect of eczema on work, life, or social activities.²



Not an actual patient.

Important Safety Information

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

- Breathing problems or wheezing
- Swelling of the face, lips, mouth, tongue, or throat
- Fainting, dizziness, feeling lightheaded
- Fast pulse
- Swollen lymph nodes
- Joint pain
- Fever
- Skin rash (red or rough skin)
- Nausea or vomiting
- General ill feeling
- Cramps in your stomach area



~Once-monthly
dosing from the start



LEARN TO USE NEMLUVIO
by scanning the code

Uniquely designed with you in mind



NEMLUVIO is the first and only self-injectable treatment for eczema (atopic dermatitis) that you can use approximately once a month from the start.^{1,8}

- The recommended dose for adults and adolescents (age 12 or older) is one 30-mg injection every 4 weeks after the initial dose of two 30-mg injections¹
- NEMLUVIO is NOT a steroid, cream, or immunosuppressant and requires no preliminary lab evaluations or ongoing lab monitoring during treatment¹
- NEMLUVIO is the first and only biologic treatment for eczema with injection site reactions as low as 1%^{1,8-10}



NEMLUVIO may be stored at room temperature up to 77 °F (25 °C) for up to 90 days making it easy to take on the go.¹

- Be sure to mark the date after NEMLUVIO is removed from the refrigerator. NEMLUVIO may be stored in the refrigerator at 36 °F to 46 °F (2 °C to 8 °C) until the expiration date¹



Review the NEMLUVIO Instructions for Use with a dermatologist before you start injections. For additional support, ask about injection training with GPS (Galderma Patient Services) for NEMLUVIO™.

Please see full [Prescribing Information](#), including Patient Information.



Key questions to ask a dermatologist

1 | Is NEMLUVIO right for me?

2 | How does NEMLUVIO block signals for itch in eczema?

3 | How is itch relief with NEMLUVIO different than other treatments I've tried?

4 | When can I expect to see results with NEMLUVIO?

5 | What is the safety profile for NEMLUVIO?

Important Safety Information

The most common side effects of NEMLUVIO include:

- Headache
- Joint pain
- Hives (itchy red rash or wheals)
- Muscle aches

These are not all of the possible side effects of NEMLUVIO.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800- FDA-1088.

Please see full [Prescribing Information](#), including Patient Information.

Let's navigate NEMLUVIO together

We're here for you from day 1. Your GPS (Galderma Patient Services) for NEMLUVIO™ support team will help you understand insurance benefits and financial assistance, provide one-on-one education, and help you stay on track, including refill reminders.



Financial support and insurance assistance

Talk to your dermatologist or the GPS for NEMLUVIO support team to see whether you are eligible for financial support. You may be able to access a **\$0 co-pay**, receive complimentary doses during insurance transitions or delays via the **Bridge Program**, or gain access to NEMLUVIO if your insurance is unable to cover treatment with the **Patient Assistance Program**.*

Nurse Navigator support

A Nurse Navigator will be available to help you manage your treatment successfully by providing:

- **Support for starting NEMLUVIO**, including virtual injection training
- **Quarterly check-ins** upon request to track your progress

Nurse Navigators can give support and education but not medical advice. If you are seeking medical advice, always consult your dermatologist.

*See eligibility requirements and terms of use.



Actor portrayal.



Start your enrollment today

Enrolling with GPS for NEMLUVIO is easy. Complete your enrollment online and we'll be in touch to connect you with the support you need.



ENROLL WITH GPS FOR NEMLUVIO
online by scanning the code

To speak with a Nurse Navigator or enroll over the phone, call 1-855-NEMLUVIO, 8:00 AM - 8:00 PM ET, Monday - Friday.



Not an actual patient.

References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 2. Galderma Laboratories, L.P.; data on file. 3. National Eczema Association. Atopic Dermatitis. Accessed October 11, 2024. <https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/> 4. Silverberg JI, Mohawk JA, Cirulli J, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. *Dermatitis*. 2023;34(2):135-144. doi:10.1089/derm.2022.29015.jsi 5. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. *Front Med (Lausanne)*. 2021;8:639097. doi:10.3389/fmed.2021.639097

References (continued): 6. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. *Expert Rev Clin Immunol*. 2021;17(8):835-852. doi:10.1080/1744666X.2021.1940962 7. Hänel KH, Pfaff CM, Cornelissen C, et al. Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network. *J Immunol*. 2016;196(8):3233-3244. doi:10.4049/jimmunol.1402943 8. DUPIXENT Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc.; 2024. 9. ADBRY Prescribing Information. LEO Pharma Inc.; 2024. 10. EBGLYSS Prescribing Information. Lilly USA, LLC.; 2024.

Your next steps for itch relief fast with skin healing that lasts in eczema^{1,2}

1 | Ask your dermatologist if NEMLUVIO
could be right for you

2 | Get started with GPS for NEMLUVIO today

Learn more about support from GPS (Galderma Patient Services)
for NEMLUVIO™ and how to complete enrollment at nemluvio.com.

For more information, you can call 1-855-NEMLUVIO,
8:00 AM - 8:00 PM ET, Monday - Friday.

3 | Sign up to stay connected

Receive ongoing education, guidance, and resources to help
along your treatment experience with NEMLUVIO.



SCAN TO SIGN UP

Important Safety Information

Indication: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age.

Please see full [Prescribing Information](#), including Patient Information.



GALDERMA

EST. 1981

©2024 Galderma Laboratories, L.P. All Rights Reserved.
NEMLUVIO is a registered trademark of Galderma.

US-NAD-2400081 12/24

FOLLOW US ON SOCIAL



@nemluvio_nemolizumab



@NEMLUVIO® (nemolizumab-ilto)